Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.

In an exclusive interaction with Business Today, Sharma called the ongoing correction a ‘bear market’, which he said, might ...